<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114115">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01617629</url>
  </required_header>
  <id_info>
    <org_study_id>CAN-003X</org_study_id>
    <nct_id>NCT01617629</nct_id>
  </id_info>
  <brief_title>Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study</brief_title>
  <acronym>CAN-003X</acronym>
  <official_title>An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prima BioMed Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prima BioMed Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess the safety profile of Cvac for epithelial ovarian
      cancer patients who were enrolled in the Cvac clinical trial CAN-003 and are no longer
      eligible for study participation due to disease progression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety will be measured through review of the number and type of adverse events associated with Cvac at all timepoints for each patient and across patients.</measure>
    <time_frame>1 Year of active dosing</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>For eligible patients that have completed or terminated the study, the collection of Overall Survival data will continue through October 2015.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Cvac Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive MUC1 Dendritic Cell Vaccine (Cvac) treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MUC1 Dendritic Cell Vaccine (Cvac)</intervention_name>
    <description>The recommended dosing regimen for CAN-003X is every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).
Patients who received more than 3 doses of Cvac in CAN-003 should continue with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks)</description>
    <arm_group_label>Cvac Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients ≥ 18 years old with histologically confirmed Stage III or IV
             epithelial ovarian, primary peritoneal, or fallopian tube cancer who were enrolled in
             CAN-003

          -  Able and willing to undergo MNC collection (if required for patients who do not have
             available Cvac doses)

          -  Were enrolled in CAN-003 and met protocol criteria for progressive disease

          -  Wish to remain in the study and, in the investigator's judgment, the potential
             benefit of Cvac treatment outweighs the risk

          -  Must be non-pregnant and, if of childbearing potential, must use adequate birth
             control (hormonal or barrier method of birth control or abstinence) for the duration
             of the study and for 3 months after study completion

          -  Able to provide written informed consent

          -  White blood cell count (WBC) ≥ 3.0 K/μL, absolute neutrophil count ≥ 1.5 K/μL,
             hemoglobin ≥ 9.0 g/dL, and platelets ≥100,000/mm3

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Other medical conditions which preclude study participation, in the opinion of the
             investigator

          -  Receiving treatment with any other investigational product
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heidy Gray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Mason, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Eisenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marin Cancer Care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Del Priore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Recio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Collaborative Research Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffery Goh, MBBS, FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Greenslopes Private Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marin Cancer Care, Inc.</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Research Group</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33487</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenslopes Private Hospital</name>
      <address>
        <city>Greenslopes</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Apostolopoulos V, McKenzie IF. Cellular mucins: targets for immunotherapy. Crit Rev Immunol. 1994;14(3-4):293-309. Review.</citation>
    <PMID>7538768</PMID>
  </reference>
  <reference>
    <citation>Apostolopoulos V, McKenzie IF, Pietersz GA. Breast cancer immunotherapy: current status and future prospects. Immunol Cell Biol. 1996 Oct;74(5):457-64. Review.</citation>
    <PMID>8912009</PMID>
  </reference>
  <reference>
    <citation>Desai J, Mitchell P, Loveland B, et al. A phase I trial of dendritic cells pulsed with MUC1 peptide in patients with solid tumours. Proc ASCO 2002; 21:15b (A1868).</citation>
  </reference>
  <reference>
    <citation>Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol. 1997 Dec 1;159(11):5211-8.</citation>
    <PMID>9548459</PMID>
  </reference>
  <reference>
    <citation>Grossi M, Quinn MA, Thursfield VJ, Francis PA, Rome RM, Planner RS, Giles GG. Ovarian cancer: patterns of care in Victoria during 1993-1995. Med J Aust. 2002 Jul 1;177(1):11-6.</citation>
    <PMID>12088472</PMID>
  </reference>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.</citation>
    <PMID>18287387</PMID>
  </reference>
  <reference>
    <citation>Liu PY, Alberts DS, Monk BJ, Brady M, Moon J, Markman M. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol. 2007 Aug 20;25(24):3615-20.</citation>
    <PMID>17704410</PMID>
  </reference>
  <reference>
    <citation>Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000 May;82(9):1535-8. Review.</citation>
    <PMID>10789720</PMID>
  </reference>
  <reference>
    <citation>Ozols RF, Rubin SC, Thomas G, et al. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology, 4th ed. Philadelphia: Lippincott Williams &amp; Wilkins. 2005:919-922.</citation>
  </reference>
  <reference>
    <citation>Rustin GJ, Nelstrop AE, Bentzen SM, Bond SJ, McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol. 2000 Apr;18(8):1733-9.</citation>
    <PMID>10764434</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>April 4, 2017</lastchanged_date>
  <firstreceived_date>June 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cvac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
